Managing fungal and viral infections in pediatric leukemia

References

• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med.354(2), 166–178 (2006).
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol. Oncol. Clin. North Am.24(1), 35–63 (2010).
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J. Clin. Oncol.22(21), 4384–4393 (2004).
   PubMed Web of Science ®Google Scholar
• Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood110(10), 3532–3539 (2007).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia18(1), 72–77 (2004).
   PubMed Web of Science ®Google Scholar
• Hilden JM, Dinndorf PA, Meerbaum SO et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood108(2), 441–451 (2006).
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J. Antimicrob. Chemother.59(1), 5–22 (2007).
   PubMed Web of Science ®Google Scholar
• Kern WV, Klose K, Jellen-Ritter AS et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur. J. Clin. Microbiol. Infect. Dis.24(2), 111–118 (2005).
   PubMed Web of Science ®Google Scholar
• Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant.39(8), 477–482 (2007).
   PubMed Web of Science ®Google Scholar
• Groll AH, Kurz M, Schneider W et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses42(7–8), 431–442 (1999).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Caviglia I, Pistorio A et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur. J. Cancer41(10), 1439–1445 (2005).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Cesaro S, Giacchino M et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr. Infect. Dis. J.25(7), 634–639 (2006).
   PubMed Web of Science ®Google Scholar
• el-Mahallawy HA, Attia I, Ali-el-Din NH, Salem AE, Abo-el-Naga S. A prospective study on fungal infection in children with cancer. J. Med. Microbiol.51(7), 601–605 (2002).
   PubMed Web of Science ®Google Scholar
• Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J. Pediatr. Hematol. Oncol.27(3), 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Fontana V, Caviglia I et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin. Infect. Dis.45(10), 1296–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Simon A, Ammann RA, Bode U et al. Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect. Dis.8, 70 (2008).
   PubMed Web of Science ®Google Scholar
• Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. Epidemiology of paediatric invasive fungal infections and a case–control study of risk factors in acute leukaemia or post stem cell transplant. Br. J. Haematol.149(2), 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Sung L, Gamis A, Alonzo TA et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer115(5), 1100–1108 (2009).
   PubMed Web of Science ®Google Scholar
• Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park, NY)18(14 Suppl. 13), 9–14 (2004).
   PubMedGoogle Scholar
• Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr. Opin. Infect. Dis.13(6), 615–620 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis.181(1), 309–316 (2000).
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer115(20), 4745–4752 (2009).
   PubMed Web of Science ®Google Scholar
• Dehority W, Willert J, Pong A. Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature. J. Pediatr. Hematol. Oncol.31(12), 911–919 (2009).
   PubMed Web of Science ®Google Scholar
• Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr. Opin. Oncol.22(2), 138–142 (2010).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica91(7), 986–989 (2006).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA. Emerging fungal diseases. Clin. Infect. Dis.41(4), 521–526 (2005).
   PubMed Web of Science ®Google Scholar
• Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs67(13), 1803–1812 (2007).
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J. Infect. Dis.199(9), 1399–1406 (2009).
   PubMed Web of Science ®Google Scholar
• Grigull L, Beier R, Schrauder A et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses46(11–12), 441–446 (2003).
   PubMed Web of Science ®Google Scholar
• Alberth M, Majoros L, Kovalecz G et al. Significance of oral Candida infections in children with cancer. Pathol. Oncol. Res.12(4), 237–241 (2006).
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer92(6), 1349–1353 (2001).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr. Infect. Dis. J.23(7), 635–641 (2004).
   PubMed Web of Science ®Google Scholar
• Falcone M, Barzaghi N, Carosi G et al.Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore)88(3), 160–168 (2009).
   PubMed Web of Science ®Google Scholar
• Flynn PM, Shenep JL, Crawford R, Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin. Infect. Dis.20(4), 964–970 (1995).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect. Dis. Clin. North Am.14(3), 721–739 (2000).
   PubMed Web of Science ®Google Scholar
• Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: emphasis on diagnostic definition and treatment. Leuk. Res.29(5), 493–501 (2005).
   PubMed Web of Science ®Google Scholar
• Sallah S, Semelka RC, Wehbie R, Sallah W, Nguyen NP, Vos P. Hepatosplenic candidiasis in patients with acute leukaemia. Br. J. Haematol.106(3), 697–701 (1999).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol.43(4), 1818–1828 (2005).
   PubMed Web of Science ®Google Scholar
• Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature334(6182), 519–522 (1988).
   PubMed Web of Science ®Google Scholar
• Stringer SL, Stringer JR, Blase MA, Walzer PD, Cushion MT. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp. Parasitol.68(4), 450–461 (1989).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics117(4), e711–e716 (2006).
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Picardi M et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality – SEIFEM-C Report. Clin. Infect. Dis.44(11), 1524–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer98(2), 315–319 (2003).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.38(9), 1237–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev.20(4), 695–704 (2007).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr. Infect. Dis. J.26(8), 723–727 (2007).
   PubMed Web of Science ®Google Scholar
• Jimenez C, Lumbreras C, Aguado JM et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation73(3), 476–480 (2002).
   PubMed Web of Science ®Google Scholar
• Ryan M, Yeo S, Maguire A et al. Rhinocerebral zygomycosis in childhood acute lymphoblastic leukaemia. Eur. J. Pediatr.160(4), 235–238 (2001).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol.36(1), 1–53 (2010).
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Roilides E, Quiroz-Telles F et al. Infections caused by Scedosporium spp. Clin. Microbiol. Rev.21(1), 157–197 (2008).
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006. Clin. Infect. Dis.43(12), 1580–1584 (2006).
   PubMed Web of Science ®Google Scholar
• Adderson EE. Histoplasmosis in a pediatric oncology center. J. Pediatr.144(1), 100–106 (2004).
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect. Dis. Clin. North Am.20(3), 645–662, vii (2006).
   PubMed Web of Science ®Google Scholar
• Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect.33(1), 23–32 (1996).
   PubMed Web of Science ®Google Scholar
• Marina NM, Flynn PM, Rivera GK, Hughes WT. Candida tropicalis and Candida albicans fungemia in children with leukemia. Cancer68(3), 594–599 (1991).
   PubMed Web of Science ®Google Scholar
• Stokes DC, Shenep JL, Parham D, Bozeman PM, Marienchek W, Mackert PW. Role of flexible bronchoscopy in the diagnosis of pulmonary infiltrates in pediatric patients with cancer. J. Pediatr.115(4), 561–567 (1989).
   PubMed Web of Science ®Google Scholar
• Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin. Infect. Dis.46(11), 1733–1737 (2008).
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121(5), e1286–e1294 (2008).
   PubMed Web of Science ®Google Scholar
• Dahniya MH, Makkar R, Grexa E et al. Appearances of paranasal fungal sinusitis on computed tomography. Br. J. Radiol.71(843), 340–344 (1998).
   PubMed Web of Science ®Google Scholar
• Bochennek K, Abolmaali N, Wittekindt B, Schwabe D, Klingebiel T, Lehrnbecher T. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin. Microbiol. Infect.12(3), 199–201 (2006).
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis.40(12), 1762–1769 (2005).
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J. Infect. Dis.190(3), 641–649 (2004).
   PubMed Web of Science ®Google Scholar
• Castagnola E, Furfaro E, Caviglia I et al. Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin. Microbiol. Infect.16(8), 1197–1203 (2010).
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses50(Suppl. 1), 2–17 (2007).
   PubMed Web of Science ®Google Scholar
• Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin. Infect. Dis.34(7), 939–943 (2002).
   PubMed Web of Science ®Google Scholar
• Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr. Blood Cancer48(1), 28–34 (2007).
   PubMed Web of Science ®Google Scholar
• Hayden R, Pounds S, Knapp K et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr. Infect. Dis. J.27(9), 815–819 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis.42(10), 1417–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J. Infect. Dis.186(9), 1297–1306 (2002).
   PubMed Web of Science ®Google Scholar
• Meersseman W, Lagrou K, Maertens J et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am. J. Respir. Crit. Care Med.177(1), 27–34 (2008).
   PubMed Web of Science ®Google Scholar
• Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-β-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol.43(12), 5957–5962 (2005).
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E et al. B-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin. Infect. Dis.39(2), 199–205 (2004).
   PubMed Web of Science ®Google Scholar
• Senn L, Robinson JO, Schmidt S et al. 1,3-β-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin. Infect. Dis.46(6), 878–885 (2008).
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1–>3)-β-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob. Agents Chemother.50(10), 3450–3453 (2006).
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-β-D-glucan assay reactivity. Clin. Infect. Dis.46(12), 1930–1931 (2008).
   PubMed Web of Science ®Google Scholar
• Smith PB, Benjamin DK Jr, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-β-D-glucan levels in children: preliminary data for diagnostic use of the b-glucan assay in a pediatric setting. Clin. Vaccine Immunol.14(7), 924–925 (2007).
   PubMed Web of Science ®Google Scholar
• Mularoni A, Furfaro E, Faraci M et al. High Levels of β-D-glucan in immunocompromised children with proven invasive fungal disease. Clin. Vaccine Immunol.17(5), 882–883 (2010).
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis.46(12), 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration62(6), 341–347 (1995).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis.50(3), 291–322 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother.51(4), 1253–1258 (2007).
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci.21(5), 645–653 (2004).
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med.356(24), 2472–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis.34(6), 730–751 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351(14), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr. Infect. Dis. J.29(5), 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346(4), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis.48(8), 1042–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst. Rev. (4), CD007394 (2008).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis.48(5), 503–535 (2009).
   PubMed Web of Science ®Google Scholar
• Akagi T, Yamaguti K, Kawamura T, Nakumura T, Kubo K, Takemori H. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk. Lymphoma47(6), 1182–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis.42(6), 753–757 (2006).
   PubMed Web of Science ®Google Scholar
• Pyrgos V, Shoham S, Roilides E, Walsh TJ. Pneumocystis pneumonia in children. Paediatr. Respir. Rev.10(4), 192–198 (2009).
   PubMed Web of Science ®Google Scholar
• Safrin S, Finkelstein DM, Feinberg J et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim–sulfamethoxazole, dapsone–trimethoprim, and clindamycin–primaquine. ACTG 108 Study Group. Ann. Intern. Med.124(9), 792–802 (1996).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46(3), 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med.347(6), 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis.34(5), 563–571 (2002).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis.36(9), 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother.46(5), 1581–1582 (2002).
   PubMed Web of Science ®Google Scholar
• Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother.51(3), 1126–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother.47(11), 3647–3650 (2003).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother.51(1), 45–52 (2003).
   PubMed Web of Science ®Google Scholar
• Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy33(5), 381–395 (1987).
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Bernard EM, Edwards FF, Armstrong D. Combination therapy in a model of pulmonary aspergillosis. Mycoses34(7–8), 281–285 (1991).
   PubMed Web of Science ®Google Scholar
• Sugar AM, Liu XP. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J. Infect. Dis.177(6), 1660–1663 (1998).
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother.49(2), 830–832 (2005).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis.37(Suppl. 3), S188–S224 (2003).
   PubMed Web of Science ®Google Scholar
• Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist12(Suppl. 2), 2–6 (2007).
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol.24(19), 3187–3205 (2006).
   PubMed Web of Science ®Google Scholar
• Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J. Clin. Oncol.22(16), 3350–3356 (2004).
   PubMed Web of Science ®Google Scholar
• Relling MV, Boyett JM, Blanco JG et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood101(10), 3862–3867 (2003).
   PubMed Web of Science ®Google Scholar
• Ehlers S, Herbst C, Zimmermann M et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J. Clin. Oncol.28(15), 2591–2597 (2010).
   PubMed Web of Science ®Google Scholar
• Liang DC. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer. Paediatr. Drugs5(10), 673–684 (2003).
   PubMedGoogle Scholar
• Safdar A. Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections. Clin. Microbiol. Infect.13(1), 1–4 (2007).
   PubMedGoogle Scholar
• Kelleher P, Goodsall A, Mulgirigama A et al. Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis. Eur. Respir. J.27(6), 1307–1310 (2006).
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Lichtiger B et al. Recombinant interferon g1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer106(12), 2664–2671 (2006).
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez G, Ohmagari N et al. The safety of interferon-g-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer103(4), 731–739 (2005).
   PubMed Web of Science ®Google Scholar
• Grigull L, Schrauder A, Schmitt-Thomssen A, Sykora K, Welte K. Efficacy and safety of G-CSF mobilized granulocyte transfusions in four neutropenic children with sepsis and invasive fungal infection. Infection30(5), 267–271 (2002).
   PubMed Web of Science ®Google Scholar
• Mousset S, Hermann S, Klein SA et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann. Hematol.84(11), 734–741 (2005).
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med.326(13), 845–851 (1992).
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J. Infect. Dis.171(6), 1545–1552 (1995).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Intern. Med.138(9), 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood103(4), 1527–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood101(9), 3365–3372 (2003).
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer94(12), 3230–3246 (2002).
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J. Clin. Oncol.25(34), 5471–5489 (2007).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Cortes J, Alvarado G et al. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support. Care Cancer DOI: 10.1007/s00520-009-0783-3 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Siwek GT, Pfaller MA, Polgreen PM et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn. Microbiol. Infect. Dis.55(3), 209–212 (2006).
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin. Infect. Dis.42(11), 1584–1591 (2006).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl J. Med356(4), 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med.356(4), 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE5(4), e10080 (2010).
   PubMed Web of Science ®Google Scholar
• Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in The Netherlands. J. Antimicrob. Chemother.65(5), 901–905 (2010).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Reichert D et al. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J. Antimicrob. Chemother.61(4), 939–946 (2008).
   PubMed Web of Science ®Google Scholar
• Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J. Antimicrob. Chemother.61(3), 734–742 (2008).
   PubMed Web of Science ®Google Scholar
• Wade JC. Viral infections in patients with hematological malignancies. Hematology Am. Soc. Hematol. Educ. Program368–374 (2006).
   PubMedGoogle Scholar
• Christensen MS, Nielsen LP, Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. Pediatr. Blood Cancer45(7), 945–951 (2005).
   PubMed Web of Science ®Google Scholar
• Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J. Pediatr. Hematol. Oncol.31(9), 623–629 (2009).
   PubMed Web of Science ®Google Scholar
• Koskenvuo M, Mottonen M, Rahiala J et al. Respiratory viral infections in children with leukemia. Pediatr. Infect. Dis. J.27(11), 974–980 (2008).
   PubMed Web of Science ®Google Scholar
• Mendoza Sanchez MC, Ruiz-Contreras J, Vivanco JL et al. Respiratory virus infections in children with cancer or HIV infection. J. Pediatr. Hematol. Oncol.28(3), 154–159 (2006).
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics121(2), 235–243 (2008).
   PubMed Web of Science ®Google Scholar
• Chavez-Bueno S, Mejias A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr. Infect. Dis. J.26(12), 1089–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Khanna N, Widmer AF, Decker M et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin. Infect. Dis.46(3), 402–412 (2008).
   PubMed Web of Science ®Google Scholar
• de Fontbrune FS, Robin M, Porcher R et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis.45(8), 1019–1024 (2007).
   PubMed Web of Science ®Google Scholar
• Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr. Infect. Dis. J.24(10), 931–932 (2005).
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med348(9), 867–868 (2003).
   PubMed Web of Science ®Google Scholar
• Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis.39(9), 1300–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J. Infect. Dis.199(10), 1435–1441 (2009).
   PubMed Web of Science ®Google Scholar
• Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathku P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect. Control Hosp. Epidemiol.28(9), 1071–1076 (2007).
   PubMed Web of Science ®Google Scholar
• Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med.361(20), 1945–1952 (2009).
   PubMed Web of Science ®Google Scholar
• Caselli D, Carraro F, Castagnola E et al. Morbidity of pandemic H1N1 influenza in children with cancer. Pediatr. Blood Cancer55(2), 226–228 (2010).
   PubMed Web of Science ®Google Scholar
• Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit. Care Med.38(4 Suppl.), e52–e57 (2010).
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Sepkowitz KA, Huang CK et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J. Infect.60(4), 257–263 (2010).
   PubMed Web of Science ®Google Scholar
• Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients – Seattle, Washington, 2009. MMWR Morb. Mortal. Wkly Rep.58(32), 893–896 (2009).
   PubMedGoogle Scholar
• Chan PA, Connell NT, Gabonay AM et al. Oseltamivir-resistant 2009–2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin. Microbiol. Infect. DOI: 10.1111/j.1469-0691.2010.03212.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin. Infect. Dis.50(9), 1252–1255 (2010).
   PubMed Web of Science ®Google Scholar
• van den Hoogen BG, de Jong JC, Groen J et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med.7(6), 719–724 (2001).
   PubMed Web of Science ®Google Scholar
• Kahn JS. Newly discovered respiratory viruses: significance and implications. Curr. Opin. Pharmacol.7(5), 478–483 (2007).
   PubMed Web of Science ®Google Scholar
• Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br. J. Haematol.145(5), 667–669 (2009).
   PubMed Web of Science ®Google Scholar
• Kamble RT, Bollard C, Demmler G, LaSala PR, Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant.40(7), 699–700 (2007).
   PubMed Web of Science ®Google Scholar
• Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl Acad. Sci. USA102(36), 12891–12896 (2005).
   PubMed Web of Science ®Google Scholar
• Schildgen O, Muller A, Allander T et al. Human bocavirus: passenger or pathogen in acute respiratory tract infections?. Clin. Microbiol. Rev.21(2), 291–304 (2008).
   PubMed Web of Science ®Google Scholar
• Kupfer B, Vehreschild J, Cornely O et al. Severe pneumonia and human bocavirus in adult. Emerg. Infect. Dis.12(10), 1614–1616 (2006).
   PubMed Web of Science ®Google Scholar
• Koskenvuo M, Mottonen M, Waris M, Allander T, Salmi TT, Ruuskanen O. Human bocavirus in children with acute lymphoblastic leukemia. Eur. J. Pediatr.167(9), 1011–1015 (2008).
   PubMed Web of Science ®Google Scholar
• Schenk T, Strahm B, Kontny U, Hufnagel M, Neumann-Haefelin D, Falcone V. Disseminated bocavirus infection after stem cell transplant. Emerg. Infect. Dis.13(9), 1425–1427 (2007).
   PubMed Web of Science ®Google Scholar
• Longtin J, Bastien M, Gilca R et al. Human bocavirus infections in hospitalized children and adults. Emerg. Infect. Dis.14(2), 217–221 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J. Pediatr. Hematol. Oncol.29(4), 227–232 (2007).
   PubMed Web of Science ®Google Scholar
• Nolan A. Interventions for prevention and treatment of herpes simplex virus in cancer patients. Evid. Based Dent.10(4), 116–117 (2009).
   PubMedGoogle Scholar
• Yahav D, Gafter-Gvili A, Muchtar E et al. Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Eur. J. Cancer45(18), 3131–3148 (2009).
   PubMed Web of Science ®Google Scholar
• Hill G, Chauvenet AR, Lovato J, McLean TW. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics116(4), e525–e529 (2005).
   PubMed Web of Science ®Google Scholar
• Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl J. Med325(22), 1545–1550 (1991).
   PubMed Web of Science ®Google Scholar
• Gershon AA, Steinberg SP, Gelb L et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA252(3), 355–362 (1984).
   PubMed Web of Science ®Google Scholar
• Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics78(4 Pt 2), 757–762 (1986).
   PubMed Web of Science ®Google Scholar
• Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation – a randomized double-blind placebo-controlled study. Blood107(5), 1800–1805 (2006).
   PubMed Web of Science ®Google Scholar
• Chemaly RF, Torres HA, Hachem R, Kontoyiannis DP, Safdar A, Raad II. Human herpesvirus-6 DNAemia in immunosuppressed adult patients with leukemia at risk for mold infection. Haematologica93(1), 157–158 (2008).
   PubMed Web of Science ®Google Scholar
• Kasahara Y, Yachie A, Takei K et al. Differential cellular targets of Epstein–Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood98(6), 1882–1888 (2001).
   PubMed Web of Science ®Google Scholar
• Hough R, Chetwood A, Sinfield R, Welch J, Vora A. Fatal adenovirus hepatitis during standard chemotherapy for childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol.27(2), 67–72 (2005).
   PubMed Web of Science ®Google Scholar
• Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet358(9279), 384–385 (2001).
   PubMed Web of Science ®Google Scholar
• Lion T, Baumgartinger R, Watzinger F et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood102(3), 1114–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Ribaud P, Eyrich M et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant.31(6), 481–486 (2003).
   PubMed Web of Science ®Google Scholar
• Arav-Boger R, Echavarria M, Forman M, Charache P, Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr. Infect. Dis. J.19(11), 1097–1100 (2000).
   PubMed Web of Science ®Google Scholar
• Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis.32(9), 1290–1297 (2001).
   PubMedGoogle Scholar
• Feuchtinger T, Matthes-Martin S, Richard C et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol.134(1), 64–76 (2006).
   PubMed Web of Science ®Google Scholar
• Lindblom A, Heyman M, Gustafsson I et al. Parvovirus B19 infection in children with acute lymphoblastic leukemia is associated with cytopenia resulting in prolonged interruptions of chemotherapy. Clin. Infect. Dis.46(4), 528–536 (2008).
   PubMed Web of Science ®Google Scholar
• Soliman Oel S, Abd El-Aal Hegazi Hasan M, El-Ashry R, Zaghloul MH, Kora B. Parvovirus B19 infection in pediatric oncology patients: diagnostic value of clinical and serologic parameters compared with nested PCR. J. Pediatr. Hematol. Oncol.31(3), 173–176 (2009).
   PubMed Web of Science ®Google Scholar
• El-Mahallawy HA, Mansour T, El-Din SE, Hafez M, Abd-el-Latif S. Parvovirus B19 infection as a cause of anemia in pediatric acute lymphoblastic leukemia patients during maintenance chemotherapy. J. Pediatr. Hematol. Oncol.26(7), 403–406 (2004).
   PubMed Web of Science ®Google Scholar
• Inaba H, Jones DP, Gaber LW et al. BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia. J. Pediatr.151(2), 215–217 (2007).
   PubMed Web of Science ®Google Scholar
• van der Bij A, Betjes M, Weening J et al. BK virus nephropathy in an immunodeficient patient with chronic lymphocytic leukemia. J. Clin. Virol.45(4), 341–344 (2009).
   PubMed Web of Science ®Google Scholar
• Cheerva AC, Raj A, Bertolone SJ, Bertolone K, Silverman CL. BK virus-associated hemorrhagic cystitis in pediatric cancer patients receiving high-dose cyclophosphamide. J. Pediatr. Hematol. Oncol.29(9), 617–621 (2007).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Facchin C, Tridello G et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant.41(4), 363–370 (2008).
   PubMed Web of Science ®Google Scholar
• Erard V, Kim HW, Corey L et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood106(3), 1130–1132 (2005).
   PubMed Web of Science ®Google Scholar
• Erard V, Storer B, Corey L et al. BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. Clin. Infect. Dis.39(12), 1861–1865 (2004).
   PubMed Web of Science ®Google Scholar
• Cesaro S, Hirsch HH, Faraci M et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin. Infect. Dis.49(2), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Ganguly N, Clough LA, Dubois LK et al. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transpl. Infect. Dis. DOI: 10.1111/j.1399-3062.2010.00513.x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Lamoth F, Pascual M, Erard V, Venetz JP, Nseir G, Meylan P. Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. Antivir. Ther.13(8), 1001–1009 (2008).
   PubMed Web of Science ®Google Scholar
• Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant.39(12), 783–787 (2007).
   PubMed Web of Science ®Google Scholar
• Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am. J. Hematol.81(7), 535–537 (2006).
   PubMed Web of Science ®Google Scholar
• Hilton R, Tong CY. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J. Antimicrob. Chemother.62(5), 855–859 (2008).
   PubMed Web of Science ®Google Scholar
• Williams JW, Javaid B, Kadambi PV et al. Leflunomide for polyomavirus type BK nephropathy. N. Engl. J. Med.352(11), 1157–1158 (2005).
   PubMed Web of Science ®Google Scholar
• Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-15), 1–48 (2006).
   PubMedGoogle Scholar
• Policy statement – recommended childhood and adolescent immunization schedules – United States, 2010. Pediatrics125(1), 195–196 (2010).
   PubMed Web of Science ®Google Scholar
• Timitilli A, Bertoluzzo L, Micalizzi C et al. Anti-varicella-zoster vaccination in contacts of children receiving antineoplastic chemotherapy: a prospective pilot study. Infez. Med.16(3), 144–147 (2008).
   PubMedGoogle Scholar
• van Tilburg CM, Sanders EA, Rovers MM, Wolfs TF, Bierings MB. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia20(10), 1717–1722 (2006).
   PubMed Web of Science ®Google Scholar
• Patel SR, Ortin M, Cohen BJ et al. Revaccination of children after completion of standard chemotherapy for acute leukemia. Clin. Infect. Dis.44(5), 635–642 (2007).
   PubMed Web of Science ®Google Scholar
• Zengin E, Sarper N. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination. Pediatr. Blood Cancer53(6), 967–972 (2009).
   PubMed Web of Science ®Google Scholar
• Ercan TE, Soycan LY, Apak H et al. Antibody titers and immune response to diphtheria–tetanus–pertussis and measles–mumps–rubella vaccination in children treated for acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol.27(5), 273–277 (2005).
   PubMed Web of Science ®Google Scholar
• Baytan B, Gunes AM, Gunay U. Efficacy of primary hepatitis B immunization in children with acute lymphoblastic leukemia. Indian Pediatr.45(4), 265–270 (2008).
   PubMed Web of Science ®Google Scholar
• Yetgin S, Tavil B, Aytac S, Kuskonmaz B, Kanra G. Unexpected protection from infection by two booster hepatitis B virus vaccination in children with acute lymphoblastic leukemia. Leuk. Res.31(4), 493–496 (2007).
   PubMed Web of Science ®Google Scholar
• Pini G, Faggi E, Donato R, Sacco C, Fanci R. Invasive pulmonary aspergillosis in neutropenic patients and the influence of hospital renovation. Mycoses51(2), 117–122 (2008).
   PubMed Web of Science ®Google Scholar
• Cornet M, Levy V, Fleury L et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect. Control Hosp. Epidemiol.20(7), 508–513 (1999).
   PubMed Web of Science ®Google Scholar
• Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL Jr. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect. Control Hosp. Epidemiol.23(9), 525–531 (2002).
   PubMed Web of Science ®Google Scholar
• Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am. J. Hematol.66(4), 257–262 (2001).
   PubMed Web of Science ®Google Scholar
• Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence?. J. Hosp. Infect.56(2), 93–100 (2004).
   PubMed Web of Science ®Google Scholar
• Galgiani JN, Ampel NM, Blair JE et al. Coccidioidomycosis. Clin. Infect. Dis.41(9), 1217–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin. Infect. Dis.46(12), 1801–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Freifeld AG, Kleiman MB et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis.45(7), 807–825 (2007).
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin. Infect. Dis.45(10), 1255–1265 (2007).
   PubMed Web of Science ®Google Scholar